Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/PKN2_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/PKN2_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/PKN2_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/PKN2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/PKN2_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/PKN2_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/PKN2_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/PKN2_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/PKN2_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/PKN2_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/PKN2_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000704311 | Stomach | CAG with IM | cell-cell junction assembly | 19/1050 | 146/18723 | 5.29e-04 | 7.94e-03 | 19 |
GO:003432911 | Stomach | CAG with IM | cell junction assembly | 38/1050 | 420/18723 | 2.56e-03 | 2.50e-02 | 38 |
GO:004506911 | Stomach | CAG with IM | regulation of viral genome replication | 12/1050 | 85/18723 | 2.71e-03 | 2.61e-02 | 12 |
GO:001603221 | Stomach | CSG | viral process | 53/1034 | 415/18723 | 1.07e-08 | 9.41e-07 | 53 |
GO:001905821 | Stomach | CSG | viral life cycle | 43/1034 | 317/18723 | 4.65e-08 | 3.47e-06 | 43 |
GO:004521621 | Stomach | CSG | cell-cell junction organization | 29/1034 | 200/18723 | 1.82e-06 | 8.48e-05 | 29 |
GO:001907921 | Stomach | CSG | viral genome replication | 19/1034 | 131/18723 | 1.05e-04 | 2.29e-03 | 19 |
GO:005079221 | Stomach | CSG | regulation of viral process | 21/1034 | 164/18723 | 2.81e-04 | 5.00e-03 | 21 |
GO:004329721 | Stomach | CSG | apical junction assembly | 13/1034 | 78/18723 | 3.20e-04 | 5.43e-03 | 13 |
GO:190390021 | Stomach | CSG | regulation of viral life cycle | 19/1034 | 148/18723 | 5.21e-04 | 7.89e-03 | 19 |
GO:000704321 | Stomach | CSG | cell-cell junction assembly | 18/1034 | 146/18723 | 1.16e-03 | 1.42e-02 | 18 |
GO:003432921 | Stomach | CSG | cell junction assembly | 37/1034 | 420/18723 | 3.50e-03 | 3.15e-02 | 37 |
GO:000166711 | Stomach | CSG | ameboidal-type cell migration | 40/1034 | 475/18723 | 5.35e-03 | 4.31e-02 | 40 |
GO:0016032113 | Thyroid | PTC | viral process | 236/5968 | 415/18723 | 2.48e-26 | 8.24e-24 | 236 |
GO:0019058113 | Thyroid | PTC | viral life cycle | 167/5968 | 317/18723 | 8.87e-15 | 5.89e-13 | 167 |
GO:000734619 | Thyroid | PTC | regulation of mitotic cell cycle | 212/5968 | 457/18723 | 4.03e-11 | 1.44e-09 | 212 |
GO:0048524112 | Thyroid | PTC | positive regulation of viral process | 44/5968 | 65/18723 | 3.24e-09 | 8.76e-08 | 44 |
GO:0019079113 | Thyroid | PTC | viral genome replication | 74/5968 | 131/18723 | 4.85e-09 | 1.26e-07 | 74 |
GO:0050792113 | Thyroid | PTC | regulation of viral process | 85/5968 | 164/18723 | 8.33e-08 | 1.70e-06 | 85 |
GO:004578718 | Thyroid | PTC | positive regulation of cell cycle | 144/5968 | 313/18723 | 9.93e-08 | 1.99e-06 | 144 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PKN2 | SNV | Missense_Mutation | | c.1450N>A | p.Glu484Lys | p.E484K | Q16513 | protein_coding | deleterious(0) | probably_damaging(0.985) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
PKN2 | SNV | Missense_Mutation | rs200905692 | c.2900C>T | p.Ser967Leu | p.S967L | Q16513 | protein_coding | tolerated(0.07) | benign(0.003) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PKN2 | SNV | Missense_Mutation | | c.164A>C | p.Glu55Ala | p.E55A | Q16513 | protein_coding | tolerated(0.32) | probably_damaging(0.989) | TCGA-AR-A1AU-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
PKN2 | SNV | Missense_Mutation | | c.2692N>T | p.Arg898Trp | p.R898W | Q16513 | protein_coding | deleterious(0) | possibly_damaging(0.727) | TCGA-BH-A0DK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
PKN2 | SNV | Missense_Mutation | | c.2479G>A | p.Glu827Lys | p.E827K | Q16513 | protein_coding | deleterious(0) | probably_damaging(0.98) | TCGA-C8-A26Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PKN2 | SNV | Missense_Mutation | | c.2479N>C | p.Glu827Gln | p.E827Q | Q16513 | protein_coding | deleterious(0) | probably_damaging(0.932) | TCGA-D8-A1JD-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
PKN2 | SNV | Missense_Mutation | novel | c.2371N>A | p.Asp791Asn | p.D791N | Q16513 | protein_coding | deleterious(0.01) | probably_damaging(0.971) | TCGA-S3-AA17-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | anastrozole | SD |
PKN2 | insertion | Frame_Shift_Ins | novel | c.463_464insTCAAGACTAGCCTGGCCAAGATGGTGAAACC | p.Ala155ValfsTer57 | p.A155Vfs*57 | Q16513 | protein_coding | | | TCGA-A2-A0EY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
PKN2 | insertion | Frame_Shift_Ins | novel | c.232_233insACATACAAAT | p.Ser78AsnfsTer17 | p.S78Nfs*17 | Q16513 | protein_coding | | | TCGA-AC-A3QQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PKN2 | insertion | Frame_Shift_Ins | novel | c.1148_1149insC | p.Leu384SerfsTer5 | p.L384Sfs*5 | Q16513 | protein_coding | | | TCGA-AC-A3QQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5586 | PKN2 | DRUGGABLE GENOME, KINASE, ENZYME, SERINE THREONINE KINASE | | PF-562271 | PF-00562271 | |
5586 | PKN2 | DRUGGABLE GENOME, KINASE, ENZYME, SERINE THREONINE KINASE | | ERLOTINIB | ERLOTINIB | |
5586 | PKN2 | DRUGGABLE GENOME, KINASE, ENZYME, SERINE THREONINE KINASE | | DOVITINIB | DOVITINIB | |
5586 | PKN2 | DRUGGABLE GENOME, KINASE, ENZYME, SERINE THREONINE KINASE | | BAY-613606 | CHEMBL541400 | |
5586 | PKN2 | DRUGGABLE GENOME, KINASE, ENZYME, SERINE THREONINE KINASE | inhibitor | 178101973 | | |
5586 | PKN2 | DRUGGABLE GENOME, KINASE, ENZYME, SERINE THREONINE KINASE | | ENTRECTINIB | ENTRECTINIB | |
5586 | PKN2 | DRUGGABLE GENOME, KINASE, ENZYME, SERINE THREONINE KINASE | | RG-1530 | RG-1530 | |
5586 | PKN2 | DRUGGABLE GENOME, KINASE, ENZYME, SERINE THREONINE KINASE | | ILORASERTIB | ILORASERTIB | |
5586 | PKN2 | DRUGGABLE GENOME, KINASE, ENZYME, SERINE THREONINE KINASE | | 681640 | CHEMBL379975 | |
5586 | PKN2 | DRUGGABLE GENOME, KINASE, ENZYME, SERINE THREONINE KINASE | | DASATINIB | DASATINIB | |